Namaste Announces Medical Cannabis Supply Agreement with Tetra Natural Health

Published: May 18, 2018

Namaste Announces Medical Cannabis Supply Agreement with Tetra Natural Health

Namaste Technologies Inc. has signed a supply agreement for the sale and distribution of RX Princeps the medicinal marijuana brand of Tetra Natural Health, a division of Tetra Bio-Pharma, whereby Namaste will purchase RX Princeps  rom Tetra Natural Health which will be sold through Namaste’s wholly owned subsidiary and Access to Cannabis for Medical Purposes medical cannabis “sales-only” facility, Cannmart Inc. In anticipation of receiving Cannmart’s sales license, the Company is focused on procuring cannabis from strategic partners to offer through its platform.


“We are thrilled to have signed this partnership deal with Namaste who operate as an e-Commerce Medicinal Cannabis distributor with 32 sites in 20 countries, providing substantial exposure forTetra Natural Health’s RX Princeps brand of medicinal marijuana,” said Guy Chamberland, CEO of Tetra Bio-Pharma, “We believe this is the making of a solid partnership with Tetra Natural Health’s ability to produce a quality product combined with Namaste’s far reaching sales and distribution network.”


Tetra Bio-Pharma is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers. In anticipation of receiving its sales license, Namaste is now focused on ramping up inventory purchasing of a carefully curated selection of high-quality medical cannabis products that will bring value to its patients.


Rx Princeps™ is a unique blend of the strains of medical cannabis. Its production has been standardized in order to ensure a lot-to-lot consistent composition in its active ingredients (THC and CBD).


“We are very proud to be bringing on a strong supply partner like Tetra Bio-Pharma,” added Sean Dollinger, President and CEO of Namaste, “RX Princeps is a unique pharma-based product that we feel will be very valuable for our patients. We have a unique opportunity to develop an exciting platform that will cater specifically to a patients’ needs.”